Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Scotet

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Immunological Reviews|February 13, 2007
Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?Aurélie Thedrez, Caroline Sabourin, Julie Gertner, et al.
Oncoimmunology|May 6, 2015
Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapyInge M Werter, Famke L Schneiders, Emmanuel Scotet, et al.
Blood|October 18, 2003
Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1Elise Landais, Xavier Saulquin, Emmanuel Scotet, et al.
Blood|March 17, 2007
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cellsAurelie Thedrez, Claudia de Lalla, Sophie Allain, et al.
European Journal of Immunology|April 8, 2017
Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activationLisa Starick, Felipe Riano, Mohindar M Karunakaran, et al.
Immunity|April 8, 2014
The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cellsAndrew Sandstrom, Cassie-Marie Peigné, Alexandra Léger, et al.
Journal for Immunotherapy of Cancer|December 3, 2025
Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALLAudrey Grain, Jocelyn Ollier, Baptiste Le Calvez, et al.
Oncoimmunology|July 30, 2016
Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumorsUlrich Jarry, Cynthia Chauvin, Noémie Joalland, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 7, 2013
Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cellsBozgana A Mangan, Margaret R Dunne, Vincent P O'Reilly, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2004
Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cellsKarsten Fischer, Emmanuel Scotet, Marcus Niemeyer, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Immunological Reviews|February 13, 2007
Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?Aurélie Thedrez, Caroline Sabourin, Julie Gertner, et al.
Oncoimmunology|May 6, 2015
Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapyInge M Werter, Famke L Schneiders, Emmanuel Scotet, et al.
Blood|October 18, 2003
Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1Elise Landais, Xavier Saulquin, Emmanuel Scotet, et al.
Blood|March 17, 2007
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cellsAurelie Thedrez, Claudia de Lalla, Sophie Allain, et al.
European Journal of Immunology|April 8, 2017
Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activationLisa Starick, Felipe Riano, Mohindar M Karunakaran, et al.
Immunity|April 8, 2014
The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cellsAndrew Sandstrom, Cassie-Marie Peigné, Alexandra Léger, et al.
Journal for Immunotherapy of Cancer|December 3, 2025
Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALLAudrey Grain, Jocelyn Ollier, Baptiste Le Calvez, et al.
Oncoimmunology|July 30, 2016
Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumorsUlrich Jarry, Cynthia Chauvin, Noémie Joalland, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 7, 2013
Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cellsBozgana A Mangan, Margaret R Dunne, Vincent P O'Reilly, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2004
Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cellsKarsten Fischer, Emmanuel Scotet, Marcus Niemeyer, et al.
Pageof 7